Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias? [electronic resource]
Producer: 20100427Description: 531-3 p. digitalISSN:- 1432-0584
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Drug Administration Schedule
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Models, Theoretical
- Neoadjuvant Therapy
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins c-abl -- antagonists & inhibitors
- Risk Factors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.